Metraipolis › archive › dc_7111f0eb46b9

Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference? — Europe PMC PMID:41155959

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41155959
DOI
10.3390/pharmaceutics17101323
License (as archived)
solo-consultazione
Archived
2026-11-09T09:37:58.079Z
SHA-256 of the archived text
ecc9241297ef424e0b73a568ffbc9417782f6ed725df5089ed08b8a6f0c71ac3
Stable URL of this page
https://metraipolis.com/documento/dc_7111f0eb46b9

How to cite

Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference? — Europe PMC PMID:41155959 — Europe PMC (en), https://europepmc.org/article/MED/41155959 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7111f0eb46b9 (Metraipolis archive dc_7111f0eb46b9, sha256 ecc9241297ef424e0b73a568ffbc9417782f6ed725df5089ed08b8a6f0c71ac3)
BibTeX
@misc{dc7111f0eb46b9,
  title = {Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference? — Europe PMC PMID:41155959},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41155959},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7111f0eb46b9; sha256 ecc9241297ef424e0b73a568ffbc9417782f6ed725df5089ed08b8a6f0c71ac3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41155959. Agents can read the archived copy with the MCP tool read_document.